{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/herpes-simplex-genital/management/first-episode/","result":{"pageContext":{"chapter":{"id":"6a765e6a-67a6-5ad9-a9da-9d4eb4d0b5ce","slug":"first-episode","fullItemName":"Scenario: First episode","depth":2,"htmlHeader":"<!-- begin field 1097c6aa-cb1e-4fba-ad22-70ee901cc01a --><h2>Scenario: First episode</h2><!-- end field 1097c6aa-cb1e-4fba-ad22-70ee901cc01a -->","summary":"Covers the assessment and management in primary care of a first episode of primary genital herpes.","htmlStringContent":"<!-- begin item 9ff61c53-ba59-4076-a48c-89002dc66ccb --><!-- begin field 6d3fa0f3-e503-40cf-a337-acbd008896c5 --><p>From age 13 years onwards.</p><!-- end field 6d3fa0f3-e503-40cf-a337-acbd008896c5 --><!-- end item 9ff61c53-ba59-4076-a48c-89002dc66ccb -->","topic":{"id":"ea9192a7-1cda-514b-8960-509d26282765","topicId":"501ea0cd-acdf-4cd7-bab7-e2043816027a","topicName":"Herpes simplex - genital","slug":"herpes-simplex-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"be649b3f-aab9-5c90-ba68-206ff0cb4be4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5247b7c3-3bd5-5827-8952-92575d834222","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f9e89c8b-9d32-562e-a793-d3d0472a139f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2fa3fae0-6a76-541b-8497-33471312a0b3","slug":"changes","fullItemName":"Changes"},{"id":"752dc01e-c669-5f0f-a6a5-8135e6adba24","slug":"update","fullItemName":"Update"}]},{"id":"b876d783-2ea3-56c8-b9b7-058854ee57ea","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d3f87500-c2da-56cd-9c46-4428e771b599","slug":"goals","fullItemName":"Goals"},{"id":"0c2f0fcc-325f-5e09-8536-f60c309bce01","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"dafa3441-13e9-5b23-8021-3a3ea3ba5f00","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c7885774-245f-5356-bbf0-70a37d6ca3f7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b6bcebe1-8904-53aa-b5d9-1754be58022e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e662dba3-03df-56c1-8cb2-d71bbba36816","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8cdad5a8-4a0a-57c0-971d-f2c81f600f55","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dd0dddfb-f2c0-5751-83c7-775739a083ee","slug":"definition","fullItemName":"Definition"},{"id":"248932d1-b0c9-5f9a-964a-1b1e6a4dde7f","slug":"causes","fullItemName":"Causes"},{"id":"e76b4902-cd2c-587d-a48d-dd59fcfc6dd2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"afd4e2b6-2ac2-5163-8ffc-e5a8a613b237","slug":"transmission","fullItemName":"Transmission"},{"id":"029f6c38-010b-500d-ba38-1bfc65b68785","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e1bc7ca7-6937-53a2-81ad-53db850f43e6","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"4b35cac6-8364-5a89-af85-9a530ac9c623","slug":"complications","fullItemName":"Complications"},{"id":"220b9c2f-04f4-5101-a56f-6fa09b02c420","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ac23dddb-072b-5c43-8b04-c85a674d3d5a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9d1e89ed-323b-5959-9318-c170832a29d0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"29beab39-2c1c-518d-a77e-9cd3b9776cad","slug":"assessment","fullItemName":"Assessment"},{"id":"0ee065d2-c568-5cf5-9f2e-0cbe67416849","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"4f2bc977-086e-5488-ab30-c8dea7c697a6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"779875c0-dc12-576e-bc57-c01d56c3b980","fullItemName":"Management","slug":"management","subChapters":[{"id":"6a765e6a-67a6-5ad9-a9da-9d4eb4d0b5ce","slug":"first-episode","fullItemName":"Scenario: First episode"},{"id":"6fabaee2-7d86-57a7-955e-be56c41f79bb","slug":"recurrent-episode","fullItemName":"Scenario: Recurrent episode"}]},{"id":"8471b333-320c-5216-bc84-578c843fbc84","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"333339e9-bc78-586f-b4a6-e65109ceb357","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b08eed31-5709-5683-9ad7-7e076ebea12d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d3573af7-fe16-5a8f-91e6-a899683376bc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cf9761b1-f157-5815-9721-f84c01bbf1de","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"71606be4-fc8b-5e02-830c-b2b2dde16541","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17f98f15-1165-5b48-a166-f0fb5335186b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8bfdd1e1-340f-50f5-ae55-79e66b213886","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"779875c0-dc12-576e-bc57-c01d56c3b980","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"bd526b27-d0eb-5f24-a8ba-420ec82f9292","slug":"treatment","fullItemName":"Treatment","depth":3,"htmlHeader":"<!-- begin field 4cd8f58d-204f-4a2d-bfc5-087294effa2a --><h3>How should I treat genital herpes?</h3><!-- end field 4cd8f58d-204f-4a2d-bfc5-087294effa2a -->","summary":null,"htmlStringContent":"<!-- begin item 96ae572b-8a5b-4562-b9fe-95bb294a9b13 --><!-- begin field e52ba023-dc61-4551-95c4-b1931aeaf2b2 --><ul><li><strong>Oral antivirals are the primary treatment for genital herpes simplex infection </strong>— treatment should commence within 5 days of the start of the episode, or while new lesions are forming for people with a first clinical episode of genital herpes simplex virus (HSV).</li><li><strong>Prescribe </strong>oral aciclovir 400 mg three times a day for 5–10 days, or 200 mg five times a day for 5–10 days, or alternatively:<ul><li>Valaciclovir 500 mg orally twice a day for 5–10 days.</li><li>Famciclovir 250 mg orally three times a day for 5–10 days.</li></ul></li><li><strong>Advise all people about appropriate <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/management/first-episode/#self-care-measures\">self care measures</a> to help relieve symptoms.</strong></li><li>Topical antiviral drugs are not recommended, as they offer minimal clinical benefit. </li></ul><!-- end field e52ba023-dc61-4551-95c4-b1931aeaf2b2 --><!-- end item 96ae572b-8a5b-4562-b9fe-95bb294a9b13 -->","subChapters":[{"id":"bff363de-e606-54ac-92df-1eba2638de7e","slug":"basis-for-recommendation-206","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 189c5cf5-bd29-4fae-9442-d44d78ffbf9f --><h4>Basis for recommendation</h4><!-- end field 189c5cf5-bd29-4fae-9442-d44d78ffbf9f -->","summary":null,"htmlStringContent":"<!-- begin item 206a096c-1825-433d-a82a-1c026296207d --><!-- begin field e246be15-8087-4bce-ab69-413f91cc547b --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK</em><em> national guideline for the management of anogenital herpes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>], the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>], the New Zealand Herpes Foundation (NZHF) <em>Guidelines for the management of genital herpes in New Zealand</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>], and a systematic review <em>Genital herpes: oral antiviral treatments</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">Hollier 2013</a>].</p><h5>Dose of antivirals and duration of treatment </h5><ul><li>Be aware that dose recommendations for antivirals and the duration of treatment may differ between guidelines for treatment of genital herpes, the Summary of Product Characteristics and the British National Formulary (BNF). <ul><li>BASHH recommends five days of antiviral treatment for primary genital HSV, as there is no evidence of benefit for treatment longer than this period [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>].</li><li>However, the WHO recommends that 10 days treatment should be provided, as follow-up visits may not be possible and symptoms of the first clinical episode may be prolonged [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>].</li></ul></li><li>CKS recommends using clinical judgement when determining the dose of antivirals and the duration of treatment.</li></ul><h5>Topical antivirals</h5><ul><li>Topical agents are less effective than oral agents, and combining oral and topical treatment is of no additional benefit over oral treatment alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>].</li></ul><h5>Choice of oral antiviral</h5><ul><li>There is no evidence of a difference in efficacy, tolerability, or toxicity between aciclovir, valaciclovir, or famciclovir in the management of primary genital herpes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">Hollier 2013</a>].</li><li>UK guidelines recommend aciclovir as first line treatment, while the NZHF recommends valaciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>].<ul><li>CKS recommends that oral aciclovir should be prescribed first-line, as it is the least expensive option. </li></ul></li></ul><!-- end field e246be15-8087-4bce-ab69-413f91cc547b --><!-- end item 206a096c-1825-433d-a82a-1c026296207d -->","subChapters":[]}]},{"id":"917f2b0f-58c4-5ed0-a999-5687a8185865","slug":"treatment-of-someone-with-hiv","fullItemName":"Treatment of someone with HIV","depth":3,"htmlHeader":"<!-- begin field 3272dd99-c12e-4b69-9672-fe5b4c9d82f7 --><h3>How should I treat someone with genital herpes simplex if they have HIV?</h3><!-- end field 3272dd99-c12e-4b69-9672-fe5b4c9d82f7 -->","summary":null,"htmlStringContent":"<!-- begin item 4b94aaf5-9607-4cab-a1da-6a9a8749dab8 --><!-- begin field ed0a98d4-3f8d-4264-9343-f7ecfe0c26ef --><ul><li>Ideally, all people with HIV and suspected genital herpes should be referred to a specialist in genito-urinary medicine (GUM) for diagnosis, treatment, screening for sexually transmitted infections (STIs), counselling regarding risks to themselves and others, and follow up (especially if they are known to have a low CD4 count).</li><li>However, if referral is declined, people with HIV can be treated in primary care provided that the infection is uncomplicated and not severe.<ul><li>Prescribe oral aciclovir 200–400 mg five times a day for 7–10 days. </li><li>Alternatively, prescribe: <ul><li>Valaciclovir 500–1000 mg twice a day for 10 days.</li><li>Famciclovir 250–500 mg three times a day for 10 days. </li></ul></li><li>If new lesions are still forming after 3–5 days, seek specialist advice.</li><li>In people with advanced HIV, double the standard dose of antiviral should be considered.</li></ul></li><li>If infection is severe, the person is systemically unwell, or complications are suspected, admit for treatment with intravenous aciclovir.<ul><li>In the absence of antiretroviral treatment, primary genital herpes may be severe and prolonged with risk of progressive, multifocal, and coalescing mucocutaneous anogenital lesions.</li><li>Complications include fulminant hepatitis, pneumonia, neurological disease, and disseminated infection.</li></ul></li><li><strong>Advise all people about appropriate <a class=\"topic-reference internal-reference\" href=\"/topics/herpes-simplex-genital/management/first-episode/#self-care-measures\">self care measures</a> to help relieve symptoms.</strong></li></ul><!-- end field ed0a98d4-3f8d-4264-9343-f7ecfe0c26ef --><!-- end item 4b94aaf5-9607-4cab-a1da-6a9a8749dab8 -->","subChapters":[{"id":"b839a097-e438-5b92-8ba0-e5b332d692ab","slug":"basis-for-recommendation-165","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 483764f3-8a33-4275-87bc-86da67a36b82 --><h4>Basis for recommendation</h4><!-- end field 483764f3-8a33-4275-87bc-86da67a36b82 -->","summary":null,"htmlStringContent":"<!-- begin item 165d669b-9602-4fa3-bfa7-98fdd1428856 --><!-- begin field b265d3ad-4fcb-4d2e-9b54-55f07648a396 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK</em><em> national guideline for the management of anogenital herpes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>], and a systematic review <em>Genital herpes: oral antiviral treatments </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">Hollier 2013</a>]<em>,</em> and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BNF 73, 2017</a>]. </p><h5>Dose of antiviral and duration of treatment </h5><ul><li>Be aware that dose recommendations for antivirals and the duration of treatment may differ between guidelines for treatment of genital herpes, the Summary of Product Characteristics and the British National Formulary (BNF). <ul><li>The WHO recommends the same dose of antivirals for primary genital HSV in people with HIV as for those without HIV. However, BASHH advises that the doses may need to be doubled [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>].</li><li>The BNF advises prescribing a dose of 500 mg famciclovir twice a day for 10 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BNF 73, 2017</a>]. </li></ul></li><li>CKS recommends using clinical judgement when determining the dose of antivirals and duration of treatment.</li></ul><h5>Choice of oral antiviral </h5><ul><li>There is no evidence to suggest that any one antiviral treatment is better than another for treating primary genital HSV in people with HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">Hollier 2013</a>].</li><li>UK guidelines recommend aciclovir as first line treatment, while the NZHF recommends valaciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>].<ul><li>CKS recommends that oral aciclovir should be prescribed first-line, as it is the least expensive option. </li></ul></li></ul><h5>Referral in people with HIV </h5><ul><li>MEDFASH provides guidance on managing people with HIV in primary care and advises seeking help from an HIV specialist if a medical condition, such as herpes simplex, is severe or resistant to treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">MEDFASH, 2016</a>].</li><li>Five days treatment is adequate for most people, including those with HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>].</li><li>BASHH recommends that if new lesions are still forming after 3–5 days of treatment, virus detection and typing should be repeated and susceptibility testing arranged in people with HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>]. <ul><li>CKS considers that specialist referral is appropriate under these circumstances.</li></ul></li></ul><!-- end field b265d3ad-4fcb-4d2e-9b54-55f07648a396 --><!-- end item 165d669b-9602-4fa3-bfa7-98fdd1428856 -->","subChapters":[]}]},{"id":"450df9c2-5041-5ad6-8436-560f3b698ac9","slug":"self-care-measures","fullItemName":"Self care measures","depth":3,"htmlHeader":"<!-- begin field 4f7c9e86-c8f4-45e3-9022-a75300e448a5 --><h3>What self care measures are suitable for people with genital herpes simplex infection?</h3><!-- end field 4f7c9e86-c8f4-45e3-9022-a75300e448a5 -->","summary":null,"htmlStringContent":"<!-- begin item 54002851-d264-48ab-95b4-a75300e4469e --><!-- begin field 2e74ce47-0bae-40af-b8ce-a75300e448a5 --><ul><li><strong>Self-care measures</strong> may be useful for some people. If appropriate, advise the person to:<ul><li>Clean the affected area with plain or salt water to help prevent secondary infection and promote healing of lesions.</li><li>Apply vaseline or a topical anaesthetic (for example lidocaine 5%) to lesions to help with painful micturition, if required.</li><li>Increase fluid intake to produce dilute urine (which is less painful to void). Urinate in a bath or with water flowing over the area to reduce stinging.</li><li>Avoid wearing tight clothing, which may irritate lesions.</li><li>Take adequate pain relief.</li><li>Avoid sharing towels and flannels with household members (although it is very unlikely that the virus would survive on an object long enough to be passed on, it is sensible to take steps to prevent this).</li></ul></li><li><strong>Advise </strong><strong>all</strong><strong> people to abstain from sexual intercourse</strong> (including non-penetrative and oro-genital sex) until follow-up or until lesions have cleared.</li></ul><!-- end field 2e74ce47-0bae-40af-b8ce-a75300e448a5 --><!-- end item 54002851-d264-48ab-95b4-a75300e4469e -->","subChapters":[{"id":"3b7bbcb1-ed29-54bf-997a-191a72175d42","slug":"basis-for-recommendation-c54","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fbbfbe09-381b-41a9-9eec-a75300e448aa --><h4>Basis for recommendation</h4><!-- end field fbbfbe09-381b-41a9-9eec-a75300e448aa -->","summary":null,"htmlStringContent":"<!-- begin item c5456bf3-bb31-4af5-bbce-a75300e448aa --><!-- begin field a47625a5-d771-4652-8dbe-a75300e448aa --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK</em><em> national guideline for the management of anogenital herpes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>], the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>], the New Zealand Herpes Foundation (NZHF) <em>Guidelines for the management of genital herpes in New Zealand</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>] and what CKS consider pragmatic advice. </p><!-- end field a47625a5-d771-4652-8dbe-a75300e448aa --><!-- end item c5456bf3-bb31-4af5-bbce-a75300e448aa -->","subChapters":[]}]},{"id":"cfb9812a-c340-5852-833a-0386add27dd9","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field e00473d6-c047-486c-91f2-5bacf2d81a7c --><h3>What advice should I give someone with herpes simplex?</h3><!-- end field e00473d6-c047-486c-91f2-5bacf2d81a7c -->","summary":null,"htmlStringContent":"<!-- begin item 3d758b0a-9f39-49e4-9653-b24bfd6b947c --><!-- begin field 403c1705-ee7c-450f-8b9e-e82d492d8db7 --><ul><li>Provide a written and verbal explanation of genital herpes simplex: the cause, signs and symptoms, transmission, complications, treatments and the prognosis, for example the Family Planning Association leaflet <a href=\"http://www.fpa.org.uk/sites/default/files/genital-herpes-information-and-advice.pdf\" data-hyperlink-id=\"2b71384b-de4a-4db2-898c-a99300740892\">Genital herpes</a>.</li><li>Explain that: <ul><li>Even with a negative swab result, they may still have genital herpes — the diagnosis can only be confirmed by a follow up test.</li><li>There is no cure for genital herpes at present.<ul><li>On average, people have 4–5 attacks of genital herpes a year after the first symptomatic episode. </li><li>However, symptoms improve (reduce in frequency and severity) with time and can be well controlled.</li></ul></li><li>A first clinical episode may not necessarily indicate recent infection (or that a partner has been unfaithful). A subclinical infection could have been acquired years before, or a HSV 1 infection may have spread from elsewhere on the body (such as lips or fingers).</li><li>Transmission can occur when there are no symptoms (asymptomatic shedding), but the risk is higher when symptomatic. Advise the person:<ul><li>To avoid sexual intercourse (including oro-genital sex) if lesions are present.</li><li>That when used consistently and correctly, male condoms may reduce the risk of transmission.</li><li>Transmission is still possible with close skin contact, or contact with infected secretions during foreplay.</li><li>To avoid sharing towels and flannels with household members, as although it is very unlikely that the virus will be transmitted this way, it is a sensible precaution.</li></ul></li></ul></li><li>Advise people who are concerned about transmitting genital herpes to long-term partners that their partner may already be infected even if they do not have symptoms, and that they should seek advice from a specialist in GUM for screening.</li><li>Explain that further support is available from the Herpes Viruses Association's helpline 0845 123 2305 (weekdays) or <a href=\"https://herpes.org.uk/\" data-hyperlink-id=\"ebdb131e-80a0-4ad3-bb7b-a993007408c0\">website</a> if required. </li></ul><!-- end field 403c1705-ee7c-450f-8b9e-e82d492d8db7 --><!-- end item 3d758b0a-9f39-49e4-9653-b24bfd6b947c -->","subChapters":[{"id":"f97a2198-8936-56f7-8c5e-a9e655898539","slug":"basis-for-recommendation-cc3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a183447d-398e-4999-8247-d88fa9adc36d --><h4>Basis for recommendation</h4><!-- end field a183447d-398e-4999-8247-d88fa9adc36d -->","summary":null,"htmlStringContent":"<!-- begin item cc36872e-d322-4be7-9a5d-7a6430e2d257 --><!-- begin field 4c9e240d-8a4f-469c-94c9-a2e11dc4dbdb --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK</em><em> national guideline for the management of anogenital herpes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>], the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>], the New Zealand Herpes Foundation (NZHF) <em>Guidelines for the management of genital herpes in New Zealand</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>].</p><h5>Use of condoms</h5><ul><li>A 50% reduction in rate of transmission of HSV is seen in those using condoms for at least 25–60% of the time [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>].</li></ul><!-- end field 4c9e240d-8a4f-469c-94c9-a2e11dc4dbdb --><!-- end item cc36872e-d322-4be7-9a5d-7a6430e2d257 -->","subChapters":[]}]},{"id":"5e05a34f-6544-5d12-8443-59f7f7078471","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field b29c75c1-e2c1-4fc7-b5b3-e7d7223a6f7b --><h3>When should I refer someone with genital herpes simplex?</h3><!-- end field b29c75c1-e2c1-4fc7-b5b3-e7d7223a6f7b -->","summary":null,"htmlStringContent":"<!-- begin item 4692c6da-07a1-4ff3-88ec-ccbdd833585b --><!-- begin field b254589d-e00e-4844-8d3b-ae0753012214 --><ul><li>Ideally, all people with suspected genital herpes should be referred to a specialist in genito-urinary medicine for diagnosis, treatment, screening for sexually transmitted infections, counselling, and follow up.</li><li>It is essential to refer the following to the appropriate speciality:<ul><li>Women who are pregnant. </li><li>Immunocompromised individuals.<ul><li>People with HIV can be treated in primary care provided that the infection is uncomplicated and not severe. However, prompt referral is indicated if there is no response to treatment (for example, if lesions are still forming after 3–5 days of treatment).</li></ul></li><li>People with: <ul><li>Herpetic proctitis.</li><li>Severe local secondary infection.</li><li>Complications (for example urinary retention).</li><li>Systemic herpes infection (for example meningitis).</li></ul></li></ul></li></ul><!-- end field b254589d-e00e-4844-8d3b-ae0753012214 --><!-- end item 4692c6da-07a1-4ff3-88ec-ccbdd833585b -->","subChapters":[{"id":"dda1e5f2-5a76-5755-af51-d223faaeec4c","slug":"basis-for-recommendation-36d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d090a4fa-5fad-4209-86ec-91ccb54578e2 --><h4>Basis for recommendation</h4><!-- end field d090a4fa-5fad-4209-86ec-91ccb54578e2 -->","summary":null,"htmlStringContent":"<!-- begin item 36d75623-fefb-4693-a4e8-842cf2fcfe02 --><!-- begin field 8eeb8078-05f9-48cc-9a0f-3c568fb41fc7 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK</em><em> national guideline for the management of anogenital herpes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">RCGP, 2013</a>], the World Health Organization (WHO) guideline <em>Treatment of genital herpes simplex virus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">WHO, 2016</a>], the New Zealand Herpes Foundation (NZHF) <em>Guidelines for the management of genital herpes in New Zealand</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>], and the Medical Foundation for HIV and Sexual Health (MEDFASH) guideline <em>HIV in primary care: a practical guide for primary healthcare professionals in Europe</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">MEDFASH, 2016</a>].</p><h5>Referral in people with HIV </h5><ul><li>MEDFASH provides guidance on managing people with HIV in primary care and advises seeking help from an HIV specialist if a medical condition, such as herpes simplex, is severe or resistant to treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">MEDFASH, 2016</a>].</li><li>Five days treatment is adequate for most people, including those with HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>].</li><li>BASHH recommends that if new lesions are still forming after 3–5 days of treatment, virus detection and typing should be repeated and susceptibility testing arranged in people with HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BASHH, 2014</a>]. <ul><li>CKS considers that specialist referral is appropriate under these circumstances.</li></ul></li></ul><!-- end field 8eeb8078-05f9-48cc-9a0f-3c568fb41fc7 --><!-- end item 36d75623-fefb-4693-a4e8-842cf2fcfe02 -->","subChapters":[]}]},{"id":"33c198b7-b4cf-56f2-a0c1-3a0634ae5e6b","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 4a500eb3-bd4d-4bf0-9506-a74b00a0daf3 --><h3>How should a person with genital herpes simplex be followed up?</h3><!-- end field 4a500eb3-bd4d-4bf0-9506-a74b00a0daf3 -->","summary":null,"htmlStringContent":"<!-- begin item 033d8527-50ac-4081-94bd-a74b00a0d9f6 --><!-- begin field d611fc77-843e-4a91-8411-a74b00a0daf3 --><ul><li>Ideally, people should be followed up by a specialist in genito-urinary medicine (GUM). </li><li>If this is not possible, or acceptable, follow up people unwilling to attend GUM, 5–7 days after the initial appointment to: <ul><li>Discuss swab results. </li><li>Evaluate symptoms.</li><li>Complete a full sexually transmitted infection (STI) screen if appropriate.</li><li>Answer any questions the person may have.</li><li>Provide advice about recurrence and treatment options. </li></ul></li><li>Follow up once a year to:<ul><li>Assess the need for episodic or suppressive therapy.</li><li>Discuss the importance of disease transmission prevention. </li><li>Monitor psychological distress. </li></ul></li></ul><!-- end field d611fc77-843e-4a91-8411-a74b00a0daf3 --><!-- end item 033d8527-50ac-4081-94bd-a74b00a0d9f6 -->","subChapters":[{"id":"aaad490a-c953-51b9-8d72-46ece770867a","slug":"basis-for-recommendation-b32","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field dd19c27e-c955-4dd7-9063-a74b00a0dafd --><h4>Basis for recommendation</h4><!-- end field dd19c27e-c955-4dd7-9063-a74b00a0dafd -->","summary":null,"htmlStringContent":"<!-- begin item b326e171-e7bb-4ced-bdf7-a74b00a0dafd --><!-- begin field 6dec7ed1-4a5d-4b31-a579-a74b00a0dafd --><p>These recommendations are based on the British medical Journal (BMJ) best practice guide <em>Herpes simplex infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">BMJ Best Practice, 2016</a>] and the New Zealand Herpes Foundation (NZHF) <em>Guidelines for the management of genital herpes in New Zealand</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NZHF, 2015</a>].</p><!-- end field 6dec7ed1-4a5d-4b31-a579-a74b00a0dafd --><!-- end item b326e171-e7bb-4ced-bdf7-a74b00a0dafd -->","subChapters":[]}]},{"id":"99dbbdb6-7fa3-5ffb-bf6c-24c696a3a22b","slug":"suspected-sexual-abuse","fullItemName":"Suspected sexual abuse","depth":3,"htmlHeader":"<!-- begin field 7b912889-f936-4e88-aef1-603abd1f03b7 --><h3>When should I suspect sexual abuse of a young person?</h3><!-- end field 7b912889-f936-4e88-aef1-603abd1f03b7 -->","summary":null,"htmlStringContent":"<!-- begin item ad8db5e4-f117-4771-88bf-369fe94308a0 --><!-- begin field 1aea89b8-d414-40b1-8ae3-5a0159134954 --><ul><li>Although rare, consider the possibility of sexual abuse in any child or young person with genital herpes, particularly in the following circumstances:<ul><li>The child is younger than 13 years of age, unless there is clear evidence of mother-to-child transmission during birth, or of blood contamination.</li><li>The young person is aged 13–15 years, unless there is clear evidence of mother-to-child transmission during birth, blood contamination, or that the sexually transmitted infection (STI) was acquired from consensual sexual activity with a peer.</li><li>The young person is aged 16–17 years and there is no clear evidence of blood contamination or that the STI was acquired from consensual sexual activity <em>and </em>there is a clear difference in power or mental capacity between the young person and their sexual partner, in particular when the relationship is incestuous or with a person in a position of trust (such as a teacher, sports coach, minister of religion) <em>or </em>there is concern that the young person is being exploited.</li></ul></li><li>If child maltreatment is suspected, refer the young person to children's social care, following Local Safeguarding Children Board procedures.</li></ul><!-- end field 1aea89b8-d414-40b1-8ae3-5a0159134954 --><!-- end item ad8db5e4-f117-4771-88bf-369fe94308a0 -->","subChapters":[{"id":"af787d08-e145-5e4f-847e-8b9527ad930e","slug":"basis-for-recommendation-2f6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ccb3911f-952a-4230-9b04-d1c71bb6161f --><h4>Basis for recommendation</h4><!-- end field ccb3911f-952a-4230-9b04-d1c71bb6161f -->","summary":null,"htmlStringContent":"<!-- begin item 2f664bc4-6a68-499f-967f-04e6c9f4c94b --><!-- begin field dc02936a-8659-424e-8b53-9fa86d476da7 --><p>These recommendations are based on the National Institute of Health and Care Excellence (NICE) guideline <em>Child maltreatment: when to suspect maltreatment in under 18s</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-genital/references/\">NICE, 2009</a>].</p><!-- end field dc02936a-8659-424e-8b53-9fa86d476da7 --><!-- end item 2f664bc4-6a68-499f-967f-04e6c9f4c94b -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}